Tarsa Completes Phase III Oral Calcitonin Trial

Tarsa recently completed a Phase III clinical trial called the ORACAL study, assessing its oral calcitonin as a treatment for postmenopausal osteoporosis.

Tarsa Therapeutics, Inc. has finished its global Phase III ORACAL trial with once-daily oral recombinant calcitonin for the treatment of postmenopausal osteoporosis. The Phase III trial enrolled 565 postmenopausal women with osteoporosis. Calcitonin, an anti-resorptive agent, has been shown to help maintain bone mass by acting on osteoclasts to limit bone resorption.

Tarsa has also initiated a new Phase II study of oral calcitonin for the prevention of postmenopausal osteoporosis. The Phase II prevention trial is a randomized, double-blind, placebo-controlled study designed to enroll approximately 120 postmenopausal women with low bone mass at increased risk of fracture.The trial will assess efficacy in the prevention of bone loss, as well as safety and tol